vs

Side-by-side financial comparison of DigitalOcean Holdings, Inc. (DOCN) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

DigitalOcean Holdings, Inc. is the larger business by last-quarter revenue ($242.4M vs $207.3M, roughly 1.2× Ultragenyx Pharmaceutical Inc.). DigitalOcean Holdings, Inc. runs the higher net margin — 10.6% vs -62.0%, a 72.6% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 18.3%). DigitalOcean Holdings, Inc. produced more free cash flow last quarter ($31.1M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 14.5%).

DigitalOcean Holdings, Inc. is an American multinational technology company and cloud service provider. The company is headquartered in Broomfield, Colorado, US, with 15 globally distributed data centers. DigitalOcean provides developers, startups, and SMBs with cloud infrastructure-as-a-service platforms.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

DOCN vs RARE — Head-to-Head

Bigger by revenue
DOCN
DOCN
1.2× larger
DOCN
$242.4M
$207.3M
RARE
Growing faster (revenue YoY)
RARE
RARE
+7.6% gap
RARE
25.9%
18.3%
DOCN
Higher net margin
DOCN
DOCN
72.6% more per $
DOCN
10.6%
-62.0%
RARE
More free cash flow
DOCN
DOCN
$131.9M more FCF
DOCN
$31.1M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
14.5%
DOCN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DOCN
DOCN
RARE
RARE
Revenue
$242.4M
$207.3M
Net Profit
$25.7M
$-128.6M
Gross Margin
58.7%
Operating Margin
16.0%
-54.7%
Net Margin
10.6%
-62.0%
Revenue YoY
18.3%
25.9%
Net Profit YoY
40.5%
3.5%
EPS (diluted)
$0.23
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DOCN
DOCN
RARE
RARE
Q4 25
$242.4M
$207.3M
Q3 25
$229.6M
$159.9M
Q2 25
$218.7M
$166.5M
Q1 25
$210.7M
$139.3M
Q4 24
$204.9M
$164.6M
Q3 24
$198.5M
$139.5M
Q2 24
$192.5M
$147.0M
Q1 24
$184.7M
$108.8M
Net Profit
DOCN
DOCN
RARE
RARE
Q4 25
$25.7M
$-128.6M
Q3 25
$158.4M
$-180.4M
Q2 25
$37.0M
$-115.0M
Q1 25
$38.2M
$-151.1M
Q4 24
$18.3M
$-133.2M
Q3 24
$32.9M
$-133.5M
Q2 24
$19.1M
$-131.6M
Q1 24
$14.1M
$-170.7M
Gross Margin
DOCN
DOCN
RARE
RARE
Q4 25
58.7%
Q3 25
59.6%
Q2 25
59.9%
Q1 25
61.4%
Q4 24
57.1%
Q3 24
60.2%
Q2 24
61.0%
Q1 24
60.7%
Operating Margin
DOCN
DOCN
RARE
RARE
Q4 25
16.0%
-54.7%
Q3 25
19.6%
-106.9%
Q2 25
16.3%
-64.8%
Q1 25
17.9%
-102.6%
Q4 24
15.9%
-74.3%
Q3 24
12.4%
-94.6%
Q2 24
11.6%
-79.1%
Q1 24
6.2%
-151.9%
Net Margin
DOCN
DOCN
RARE
RARE
Q4 25
10.6%
-62.0%
Q3 25
69.0%
-112.8%
Q2 25
16.9%
-69.0%
Q1 25
18.1%
-108.5%
Q4 24
8.9%
-80.9%
Q3 24
16.6%
-95.7%
Q2 24
9.9%
-89.5%
Q1 24
7.7%
-156.8%
EPS (diluted)
DOCN
DOCN
RARE
RARE
Q4 25
$0.23
$-1.28
Q3 25
$1.51
$-1.81
Q2 25
$0.39
$-1.17
Q1 25
$0.39
$-1.57
Q4 24
$0.21
$-1.34
Q3 24
$0.33
$-1.40
Q2 24
$0.20
$-1.52
Q1 24
$0.15
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DOCN
DOCN
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$254.5M
$421.0M
Total DebtLower is stronger
$1.3B
Stockholders' EquityBook value
$-28.7M
$-80.0M
Total Assets
$1.8B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DOCN
DOCN
RARE
RARE
Q4 25
$254.5M
$421.0M
Q3 25
$236.6M
$202.5M
Q2 25
$387.7M
$176.3M
Q1 25
$360.4M
$127.1M
Q4 24
$428.4M
$174.0M
Q3 24
$439.9M
$150.6M
Q2 24
$443.1M
$480.7M
Q1 24
$419.1M
$112.3M
Total Debt
DOCN
DOCN
RARE
RARE
Q4 25
$1.3B
Q3 25
$1.3B
Q2 25
Q1 25
Q4 24
$1.5B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
DOCN
DOCN
RARE
RARE
Q4 25
$-28.7M
$-80.0M
Q3 25
$-69.6M
$9.2M
Q2 25
$-175.2M
$151.3M
Q1 25
$-210.7M
$144.2M
Q4 24
$-203.0M
$255.0M
Q3 24
$-211.7M
$346.8M
Q2 24
$-253.8M
$432.4M
Q1 24
$-286.1M
$140.3M
Total Assets
DOCN
DOCN
RARE
RARE
Q4 25
$1.8B
$1.5B
Q3 25
$1.7B
$1.2B
Q2 25
$1.7B
$1.3B
Q1 25
$1.6B
$1.3B
Q4 24
$1.6B
$1.5B
Q3 24
$1.5B
$1.5B
Q2 24
$1.5B
$1.6B
Q1 24
$1.5B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DOCN
DOCN
RARE
RARE
Operating Cash FlowLast quarter
$57.3M
$-99.8M
Free Cash FlowOCF − Capex
$31.1M
$-100.8M
FCF MarginFCF / Revenue
12.8%
-48.6%
Capex IntensityCapex / Revenue
10.8%
0.5%
Cash ConversionOCF / Net Profit
2.23×
TTM Free Cash FlowTrailing 4 quarters
$180.5M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DOCN
DOCN
RARE
RARE
Q4 25
$57.3M
$-99.8M
Q3 25
$95.8M
$-91.4M
Q2 25
$92.4M
$-108.3M
Q1 25
$64.1M
$-166.5M
Q4 24
$71.3M
$-79.3M
Q3 24
$73.4M
$-67.0M
Q2 24
$71.3M
$-77.0M
Q1 24
$66.7M
$-190.7M
Free Cash Flow
DOCN
DOCN
RARE
RARE
Q4 25
$31.1M
$-100.8M
Q3 25
$88.0M
$-92.7M
Q2 25
$59.3M
$-110.7M
Q1 25
$2.1M
$-167.8M
Q4 24
$26.1M
$-79.5M
Q3 24
$16.0M
$-68.6M
Q2 24
$39.5M
$-79.0M
Q1 24
$23.0M
$-193.9M
FCF Margin
DOCN
DOCN
RARE
RARE
Q4 25
12.8%
-48.6%
Q3 25
38.3%
-58.0%
Q2 25
27.1%
-66.5%
Q1 25
1.0%
-120.5%
Q4 24
12.7%
-48.3%
Q3 24
8.1%
-49.2%
Q2 24
20.5%
-53.7%
Q1 24
12.5%
-178.2%
Capex Intensity
DOCN
DOCN
RARE
RARE
Q4 25
10.8%
0.5%
Q3 25
3.4%
0.8%
Q2 25
15.2%
1.5%
Q1 25
29.4%
1.0%
Q4 24
22.1%
0.1%
Q3 24
28.9%
1.2%
Q2 24
16.6%
1.4%
Q1 24
23.6%
3.0%
Cash Conversion
DOCN
DOCN
RARE
RARE
Q4 25
2.23×
Q3 25
0.60×
Q2 25
2.50×
Q1 25
1.68×
Q4 24
3.91×
Q3 24
2.23×
Q2 24
3.73×
Q1 24
4.72×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DOCN
DOCN

Scalers$84.3M35%
Scalers Plus$69.9M29%
Builders$64.1M26%
Learners Testers And Other$24.1M10%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons